BPC 157 and ipamorelin under FDA scrutiny Alex Keoskey posted on the topic LinkedIn The Peptide Moment: How FDA's Regulatory Reversal Creates Risk and Opportunity for Venture Capital and Private Equity Guidepost Solutions BPC 157: Experimental Peptide Creates Risk for Athletes BREAKING: The FDA just made it official. Advisory committee meetings are now scheduled for July 23 24 to review reclassifying peptides back to legal compounding status. Here's what's happening: After the